title: Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
abstract: Meningiomas often are not amenable to total resection, and subtotally resected meningiomas often recur. Recurrent meningiomas present a clinical dilemma, particularly when surgical and radiotherapy options are exhausted, as there are no chemotherapeutic options that demonstrate consistent, significant efficacy. We report a patient with the regression of a recurrent World Health Organization grade I meningioma during combination chemotherapy with bevacizumab and paclitaxel for breast cancer. This chemotherapy regimen has never been explored for recurrent meningiomas. While further data are necessary, we suggest that combination chemotherapy with bevacizumab and paclitaxel may be an option for treatment of recurrent meningiomas when no further surgical or radiotherapy options exist.
authors.affiliation: Department of Neurosurgery, University of Michigan Health System, Ann Arbor, MI 48109-5338, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Wilson
authors.forename: Jason A
authors.initials: JA
authors.lastname: Heth
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000068258:Bevacizumab; D001921:Brain / Q000473:pathology; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008579:Meningioma / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D017239:Paclitaxel